Trimetazidine dihydrochloride

 Presentation

Angitrim MR Tablet: Each modified release tablet contains Trimetazidine Dihydrochloride BP 35 mg.

 Description

Trimetazidine has been proven to exert antianginal and anti-ischemic effect without inducing hemodynamic changes and improves the condition of ischemic myocardium. It is indicated for long term treatment of angina pectoris. Trimetazidine inhibits b-oxidation of fatty acids by blocking long-chain 3-ketoacyl-CoA thiolase, which enhances glucose oxidation. In an ischaemic cell, energy obtained during glucose oxidation requires less oxygen consumption than in the b-oxidation process. Potentiation of glucose oxidation optimizes cellular energy processes, thereby maintaining proper energy metabolism during ischaemia.

 Therapeutic Class

Anti-anginal

 

Prescribing Information